Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ASRT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 12.1% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.29M USD | Price to earnings Ratio - | 1Y Target Price 2.85 |
Price to earnings Ratio - | 1Y Target Price 2.85 | ||
Volume (30-day avg) 394345 | Beta 0.81 | 52 Weeks Range 0.65 - 1.80 | Updated Date 04/1/2025 |
52 Weeks Range 0.65 - 1.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When After Market | Estimate 0.0133 | Actual -0.03 |
Profitability
Profit Margin -17.27% | Operating Margin (TTM) -27.35% |
Management Effectiveness
Return on Assets (TTM) -4.53% | Return on Equity (TTM) -16.66% |
Valuation
Trailing PE - | Forward PE 14.99 | Enterprise Value 3498853 | Price to Sales(TTM) 0.53 |
Enterprise Value 3498853 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA 0.86 | Shares Outstanding 95773104 | Shares Floating 85686262 |
Shares Outstanding 95773104 | Shares Floating 85686262 | ||
Percent Insiders 2.71 | Percent Institutions 29.62 |
Analyst Ratings
Rating 4.5 | Target Price 3.15 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Assertio Therapeutics Inc
Company Overview
History and Background
Assertio Therapeutics Inc. was founded in 1995 as Depomed, Inc. It focused on developing and commercializing novel products for pain and other central nervous system conditions. Over time, the company has undergone strategic shifts, including acquisitions and divestitures, ultimately rebranding as Assertio Therapeutics, Inc. to reflect its current focus on specialized pharmaceutical products and efficient commercial operations.
Core Business Areas
- Neurology: Commercializes treatments for neurological conditions. Key products include those targeting migraines and other neurological disorders, aiming to improve patient outcomes in these areas.
- Pain and Inflammation: Focuses on providing prescription medications to manage acute and chronic pain, as well as anti-inflammatory products. Emphasis on medications requiring specific physician expertise to manage patients effectively.
Leadership and Structure
Assertio Therapeutics Inc. is led by a management team headed by Dan Peisert as CEO. The company operates with a functional organizational structure focused on streamlining commercial operations and maximizing the value of its product portfolio. The board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- Cambia: Cambia is a nonsteroidal anti-inflammatory drug (NSAID) used for the acute treatment of migraine attacks. While precise market share data is difficult to obtain, Cambia faces competition from other NSAIDs and triptans (such as Imitrex and Maxalt) in the migraine market. Revenue data for Cambia is a key factor for Assertio's income statements.
- Otrexup: Otrexup is a subcutaneous auto-injector containing methotrexate used to treat rheumatoid arthritis and psoriasis. Competitors include generic methotrexate formulations, as well as injectable biologics such as Humira and Enbrel. Market share data for Otrexup is not easily verifiable publicly, but is often tracked in Assertio's public disclosures.
- Indocin: Indocin is used to relieve pain, tenderness, swelling, and stiffness caused by arthritis, bursitis, and tendinitis. Its competitors include Advil, Motrin, Aleve, and Bayer. Market share data for Indocin is not easily verifiable publicly, but is often tracked in Assertio's public disclosures.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. The market for neurology and pain management products is driven by the prevalence of chronic diseases and the demand for effective treatments.
Positioning
Assertio Therapeutics Inc. occupies a niche position within the pharmaceutical industry, focusing on acquiring, developing, and commercializing specialized treatments for neurological and pain conditions. Its competitive advantage lies in its commercial capabilities and focus on select therapeutic areas.
Total Addressable Market (TAM)
The TAM for pain management and neurology pharmaceuticals is estimated to be in the tens of billions of dollars globally. Assertio Therapeutics Inc. targets specific segments within this larger market, with an increasing focus on high-value, differentiated products. Their TAM is defined by the specific indications of their medications.
Upturn SWOT Analysis
Strengths
- Focused product portfolio
- Established commercial infrastructure
- Experienced management team
- Specialized therapeutic areas
Weaknesses
- Reliance on a limited number of key products
- Competition from larger pharmaceutical companies
- Patent expirations and generic erosion
- Small market capitalization
Opportunities
- Strategic acquisitions of complementary products
- Expansion into new therapeutic areas
- Development of innovative formulations
- Partnerships with other pharmaceutical companies
Threats
- Increasing generic competition
- Regulatory changes and pricing pressures
- Product liability litigation
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- PRGO
- ENDP
Competitive Landscape
Assertio Therapeutics Inc. faces competition from larger pharmaceutical companies with greater resources and broader product portfolios. To compete effectively, Assertio focuses on niche therapeutic areas, strategic acquisitions, and efficient commercial operations.
Major Acquisitions
Zyla Life Sciences
- Year: 2020
- Acquisition Price (USD millions): 44.5
- Strategic Rationale: The acquisition of Zyla Life Sciences enhanced Assertio's product portfolio with pain management assets, increasing revenue and expanding its presence in this therapeutic area.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Assertio Therapeutics Inc. has been marked by periods of acquisitions and divestitures, leading to fluctuations in revenue and profitability. More recent growth initiatives impact this and should be considered.
Future Projections: Future growth projections depend on analyst estimates and company guidance. Details will vary depending on reports.
Recent Initiatives: Recent strategic initiatives may include acquisitions, new product launches, and cost reduction programs. These initiatives are aimed at driving revenue growth and improving profitability.
Summary
Assertio Therapeutics Inc. is a smaller player in a competitive pharmaceutical landscape. They have focused on pain and neurology product portfolio. They are challenged by generic competition and regulatory pressures. Future opportunities lie in strategic acquisitions, product development, and strong commercial execution to establish the market.
Similar Companies
PRGO
Perrigo Company PLC
PRGO
Perrigo Company PLC
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports (e.g., from investment banks)
- Industry News and Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data and financial figures are subject to change and may not be entirely accurate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Brendan P. O'Grady | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 58 | Website https://www.assertiotx.com |
Full time employees 58 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.